RNA Splicing Dysregulation in 4R-Tauopathies: A Comparative Analysis

RNA Splicing Dysregulation in 4R-Tauopathies: A Comparative Analysis

Introduction

The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the preferential accumulation of hyperphosphorylated 4-repeat (4R) tau protein isoforms. This group includes [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration (CBD/ corticobasal syndrome](/diseases/corticobasal-syndrome)), [Argyrophilic Grain Disease (AGD](/diseases/argyrophilic-grain-disease)), [Globular Glial Tauopathy (GGT](/diseases/globular-glial-tauopathy)), and [Frontotemporal Dementia with Parkinsonism-17 (FTDP-17](/genes/mapt))[@wang2024]. While these disorders share tau pathology as a common denominator, emerging evidence demonstrates that RNA splicing dysregulation — particularly involving the [MAPT](/genes/mapt) gene and splicing machinery — plays a critical pathogenic role in disease onset and progression.

This comparative analysis examines the landscape of RNA splicing defects across 4R-tauopathies, focusing on: (1) alternative splicing of MAPT exon 10 and the 4R/3R tau ratio; (2) splicing factor dysregulation including TDP-43, FUS, and SR proteins; (3) spliceosome integrity and intron retention patterns; (4) transcriptomic findings from RNA-seq studies; and (5) therapeutic approaches targeting splicing machinery[@rigo2024].

Shared Mechanisms

MAPT Exon 10 Alternative Splicing

RNA Splicing Dysregulation in 4R-Tauopathies: A Comparative Analysis

Introduction

The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the preferential accumulation of hyperphosphorylated 4-repeat (4R) tau protein isoforms. This group includes [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy), [Corticobasal Degeneration (CBD/ corticobasal syndrome](/diseases/corticobasal-syndrome)), [Argyrophilic Grain Disease (AGD](/diseases/argyrophilic-grain-disease)), [Globular Glial Tauopathy (GGT](/diseases/globular-glial-tauopathy)), and [Frontotemporal Dementia with Parkinsonism-17 (FTDP-17](/genes/mapt))[@wang2024]. While these disorders share tau pathology as a common denominator, emerging evidence demonstrates that RNA splicing dysregulation — particularly involving the [MAPT](/genes/mapt) gene and splicing machinery — plays a critical pathogenic role in disease onset and progression.

This comparative analysis examines the landscape of RNA splicing defects across 4R-tauopathies, focusing on: (1) alternative splicing of MAPT exon 10 and the 4R/3R tau ratio; (2) splicing factor dysregulation including TDP-43, FUS, and SR proteins; (3) spliceosome integrity and intron retention patterns; (4) transcriptomic findings from RNA-seq studies; and (5) therapeutic approaches targeting splicing machinery[@rigo2024].

Shared Mechanisms

MAPT Exon 10 Alternative Splicing

The [MAPT](/genes/mapt) gene encodes tau protein through alternative splicing of exon 10, which determines whether the resulting protein contains three (3R-tau) or four (4R-tau) microtubule-binding repeats. Under normal conditions, the 4R:3R ratio is approximately 1:1 in adult human brain. In 4R-tauopathies, this ratio shifts dramatically to approximately 3:1 or higher, representing one of the most consistent molecular signatures of these disorders[@chen2024].

The splicing of exon 10 is regulated by multiple cis-acting elements within the [MAPT](/genes/mapt) pre-mRNA and trans-acting factors including:

• Exonic splicing enhancers (ESEs): Bind SR proteins (SFRS1/ASF-SF2, SC35/SRSF2)
• Exonic splicing silencers (ESSs): Bind hnRNPs (hnRNPA1, hnRNPA2B1)
• Intronic splicing regulatory elements: Located in intron 10

Splicing Factor Dysregulation

Spliceosome Integrity

The spliceosome — the large ribonucleoprotein complex responsible for pre-mRNA splicing — undergoes significant alterations in 4R-tauopathies. Research has demonstrated:

• U1/U2 snRNP alterations: Changes in small nuclear ribonucleoprotein complex composition
• Spliceosome assembly defects: Impaired recruitment of splicing machinery to pre-mRNA
• Intron retention increases: Global patterns of intron retention observed in affected brain regions[@west2024]

Disease-Specific Mechanisms

Progressive Supranuclear Palsy (PSP)

[PSP](/diseases/progressive-supranuclear-palsy) shows the most pronounced 4R-tau predominance among 4R-tauopathies. The H1 haplotype of [MAPT](/genes/mapt), present in approximately 95% of PSP patients, is strongly associated with increased 4R-tau production through altered splicing regulation[@gao2024]:

• H1 haplotype effect: Increases expression of 4R isoforms through polymorphic elements influencing exon 10 splicing
• Splicing factor changes: Altered expression of SFRS1, SC35, and hnRNPs in affected brain regions
• TDP-43 involvement: Subset of PSP cases show TDP-43 pathology with consequent cryptic exon inclusion
• RNA-seq findings: Aberrant splicing of neuronal transcripts, altered MAPT splice variants[@lawton2012]

Corticobasal Degeneration (CBD/CBS)

[CBD](/diseases/corticobasal-syndrome) shares the H1 haplotype association with PSP but shows distinct regional vulnerability patterns:

• MAPT splicing: Mutations in [MAPT](/genes/mapt) can cause FTDP-17, a familial form that informs CBD mechanisms
• 4R:3R ratio: Elevated 4R-tau similar to PSP but with different cellular distribution
• TDP-43 comorbidity: Many CBD cases show TDP-43 pathology in addition to tau pathology
• Splicing dysregulation: Altered expression of splicing factors including SRSF2, HNRNPA1[@tomm2020]

Argyrophilic Grain Disease (AGD)

[AGD](/diseases/argyrophilic-grain-disease) represents the most common incidental tauopathy but can present as a primary neurodegenerative condition:

• 4R-tau predominance: Similar 4R predominance to PSP and CBD
• Splicing patterns: Limbic system splicing alterations distinct from other 4R-tauopathies[@mithihara2019]
• Epigenetic interactions: MALAT1 and NEAT1 lncRNA changes affect splicing regulation
• Regional specificity: More prominent involvement of limbic regions

Globular Glial Tauopathy (GGT)

[GGT](/diseases/globular-glial-tauopathy) is characterized by prominent glial tau pathology:

• Oligodendroglial involvement: Unique among 4R-tauopathies in the degree of glial pathology
• Splicing mechanisms: Less characterized than other 4R-tauopathies but shares 4R predominance
• MAPT mutations: Some familial cases linked to [MAPT](/genes/mapt) mutations affecting splicing

FTDP-17 (MAPT Mutations)

[FTDP-17](/genes/mapt) represents the genetic model for understanding tau splicing dysregulation:

• Disease-causing mutations: Over 50 [MAPT](/genes/mapt) mutations, many directly affect exon 10 splicing
• Splice site mutations: Mutations at splice sites flanking exon 10 disrupt normal splicing
• Exonic mutations: Mutations within exon 10 affect splicing regulatory elements
• Haplotype effects: H1/H2 haplotype status modifies mutation penetrance

Comparison Matrix

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|----------|
| 4R:3R Ratio | ~3:1 | ~3:1 | ~3:1 | ~3:1 | Variable (depends on mutation) |
| H1 Haplotype | >95% | >80% | Variable | Variable | Depends on mutation |
| TDP-43 Pathology | ~20-30% | ~40% | Rare | Rare | Variable |
| Major Splicing Targets | MAPT exon 10, neuronal transcripts | MAPT exon 10, TDP-43 targets | Limbic transcripts | Less characterized | MAPT exon 10 |
| Key Splicing Factors | SFRS1, SC35, hnRNPs | SRSF2, HNRNPA1 | MALAT1, NEAT1 | Less characterized | Multiple (mutation-specific) |
| RNA-seq Findings | Aberrant neuronal splicing | Transcriptomic changes | Limbic alterations | Limited data | Mutation-specific |

Therapeutic Implications

Antisense Oligonucleotides (ASOs)

Therapeutic strategies targeting RNA splicing are advancing rapidly[@rigo2024]:

• MAPT-targeted ASOs: ASOs designed to modulate exon 10 splicing toward normal 4R:3R ratio
• Splicing factor ASOs: Targeting dysregulated splicing factors to restore normal splicing patterns
• TDP-43 restoration: ASOs to restore proper TDP-43 nuclear localization and function

Small Molecule Modulators

• Spliceosome modulators: Compounds targeting spliceosome assembly and function
• SR protein modulators: Drugs modifying SR protein phosphorylation and activity
• lncRNA-targeting: MALAT1 and NEAT1 antagonists to restore normal splicing regulation

Clinical Trials

• NCT07348276: First human 4R-tau ligand for PSP (imaging biomarker)
• ASO trials: MAPT-targeting ASOs in early-stage trials for AD, with potential extension to 4R-tauopathies

Cross-Linked Pages

• [MAPT Gene](/genes/mapt) — Tau protein gene with splicing mutations
• [4R-Tau Proteins](/proteins/4r-tau) — Four-repeat tau isoforms
• [PSP Pathway](/mechanisms/psp-pathway) — Comprehensive PSP mechanism
• [CBD Pathway](/mechanisms/cbd-pathway) — Corticobasal degeneration mechanism
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — TDP-43 pathology in neurodegeneration
• [RNA Splicing in Neurodegeneration](/mechanisms/rna-splicing) — General RNA splicing mechanisms
• [RNA Metabolism in 4R-Tauopathies](/mechanisms/rna-metabolism-4r-tauopathies) — RNA metabolism overview
• [Cryptic Exon Splicing](/mechanisms/cryptic-exon-splicing) — TDP-43-dependent cryptic exons
• [Splice Modulation Therapeutics](/mechanisms/splice-modulation-neurodegeneration) — Therapeutic approaches

Tau Strain Diversity and Splicing

Tau Prion Strains

Recent research has revealed that tau pathology exists as distinct "strains" with different conformations and propagation properties[@sanders2020]. These strains may originate from different splicing patterns:

AD tau vs PSP tau: Cryo-EM studies show distinct tau filament structures between Alzheimer's disease and PSP[@ivanova2022]. These structural differences correlate with:

• Different exon 10 splicing patterns
• Variable post-translational modifications
• Distinct cellular vulnerability profiles

Implications for Splicing-Based Therapeutics

Understanding tau strain diversity has implications for splicing-targeted approaches:

• Strain-specific ASO design may be necessary
• Splicing modulation may need to consider prion-like propagation
• Biomarkers must account for strain heterogeneity

Model Systems for Studying Splicing Dysregulation

Cellular Models

iPSC-derived neurons: Patient-derived induced pluripotent stem cells offer insights into splicing abnormalities:

• Neurons from 4R-tauopathy patients show altered exon 10 splicing
• Isogenic lines allow study of specific genetic variants
• High-throughput screening for splicing modulators

• Layer-specific splicing patterns mirror adult brain
• Allows study of cell-type-specific splicing defects
• Disease modeling in three-dimensional culture

Animal Models

Transgenic models: Mouse models expressing mutant MAPT:

• Replicate altered 4R:3R ratio
• Show age-dependent splicing changes
• Enable testing of ASO therapeutics

Biomarker Development

Splicing-based biomarkers offer potential for early detection and disease monitoring:

Blood-based splicing markers:

• Exon skipping events detectable in plasma
• Splicing factor protein levels in exosomes
• Cell-free RNA signatures

• Tau isoform ratios (4R:3R) in CSF
• Splicing factor fragments
• Cryptic exon inclusion products

• PET ligands targeting specific tau conformations
• Correlation with splicing patterns

Future Directions

The field of RNA splicing in 4R-tauopathies is rapidly evolving. Key areas for future research include:

Unmet Needs

• Biomarker validation: Larger studies to validate splicing-based biomarkers
• Clinical trial infrastructure: Establishing endpoints for splicing-modifying therapies
• Patient stratification: Using splicing profiles to identify optimal treatment populations

Epigenetic Regulation of Splicing

DNA Methylation Effects

Epigenetic modifications influence splicing factor expression in 4R-tauopathies:

• Promoter methylation of splicing factor genes affects expression levels
• Histone modifications alter accessibility of splice sites
• Age-related epigenetic drift may contribute to sporadic disease

Non-Coding RNA Regulation

Long non-coding RNAs (lncRNAs) play important roles in splicing regulation:

MALAT1: Modulates splicing factor activity and is dysregulated in tauopathies NEAT1: Forms nuclear paraspeckles and affects alternative splicing XIST: May influence sex differences in tauopathy susceptibility

Clinical Implications

Biomarker Development

Splicing patterns in peripheral tissues may serve as biomarkers:

• Exon skipping signatures in blood RNA
• Splicing factor levels in CSF
• lncRNA panels for disease staging

Therapeutic windows

Early intervention in splicing may offer benefits:

• Preclinical studies show splicing changes precede overt tau pathology
• ASO approaches may be most effective in early disease stages
• Combination approaches targeting multiple splicing events may be needed

References